01.09.2001 | Original Article
Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles
Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2001
Einloggen, um Zugang zu erhalten